Citation Impact
Citing Papers
Oxidative Stress
2017 Standout
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism
2016 Standout
Burn wound healing and treatment: review and advancements
2015 Standout
Altered fecal microbiota composition in patients with major depressive disorder
2015 Standout
Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies
2002
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis
2018
Parkinson disease
2017 Standout
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
2018
Parkinson's disease
2021 Standout
The enduring effects of abuse and related adverse experiences in childhood
2005 Standout
Glutamate uptake
2001 Standout
Cocaine craving, euphoria, and self-administration: A preliminary study of the effect of catecholamine precursor depletion.
2005
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
2014 Standout
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
1998
Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients
2006
The interplay between the intestinal microbiota and the brain
2012 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
2016 Standout
Cytokines sing the blues: inflammation and the pathogenesis of depression
2005 Standout
The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner
2012 Standout
Parkinson's disease
2015 Standout
Gut–brain axis: how the microbiome influences anxiety and depression
2013 Standout
Interferon-alpha–induced changes in tryptophan metabolism
2003
Host microbiota constantly control maturation and function of microglia in the CNS
2015 Standout
Impulsivity as a vulnerability marker for substance-use disorders: Review of findings from high-risk research, problem gamblers and genetic association studies
2008 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Mediators and Moderators of Treatment Effects in Randomized Clinical Trials
2002 Standout
Major Depressive Disorder
2008 Standout
Non-motor features of Parkinson disease
2017 Standout
Serotonergic modulation of mismatch negativity
2005
The gut microbiota — masters of host development and physiology
2013 Standout
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
2014 Standout
The mismatch negativity (MMN) in basic research of central auditory processing: A review
2007 Standout
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
2012 Standout
Improving antibiotic dosing in special situations in the ICU
2012
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
The molecular neurobiology of depression
2008 StandoutNature
The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice
2011 Standout
The debate over dopamine’s role in reward: the case for incentive salience
2006 Standout
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
2019 Standout
Pharmacology and Clinical Drug Candidates in Redox Medicine
2015
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
2012
Therapeutic prospects for Parkinson disease
2013
The Glutamate Hypothesis of Schizophrenia
1997
Diagnosis and Treatment of Parkinson Disease
2020 Standout
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy
2002
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
2016
Gut microbiota are related to Parkinson's disease and clinical phenotype
2014 Standout
Microbial degradation of complex carbohydrates in the gut
2012 Standout
Host-Gut Microbiota Metabolic Interactions
2012 StandoutScience
How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients
2018
The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.
2015 Standout
Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing
2020 Standout
Interventions for fatigue in Parkinson's disease
2015
Works of V. Lucini being referenced
Neutral amino acid availability in two major psychiatric disorders
1995
Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man
1996
Plasma Tryptophan to Large Neutral Amino Acids Ratio and Therapeutic Response to a Selective Serotonin Uptake Inhibitor
1994
Plasma tryptophan levels and plasma tryptophan/ neutral amino acids ratio in patients with mood disorder, patients with obsessive-compulsive disorder, and normal subjects
1992
Serine and glycine metabolism in schizophrenic patients
1993
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia
2009
A randomized, double‐blind, placebo‐controlled trial of safinamide as add‐on therapy in early Parkinson's disease patients
2011
Randomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations
2013
Long‐term efficacy and safety of safinamide as add‐on therapy in early P arkinson's disease
2012
Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease
2014